INTRODUCTION AND OBJECTIVES: Following prostate Focal
Therapy(FT), a proportion of patients will develop recurrent disease and, some of them will ultimately require salvage treatment. The toxicity of radical prostatectomy after FT (S-RALP) is not clearly understood. Before widespread clinical adoption of FT, it is imperative to characterize the toxicity of secondary treatments after FT in order to counsel patients, inform clinicians and underpin guideline recommendations. Our aim is to characterize the perioperative, oncologic and functional outcomes after S-RALP.
METHODS: We included patients with histological confirmation of residual/recurrent prostate cancer (after FT) within the six months previous to radical prostatectomy. In all patients metastatic disease was excluded with a pelvic MRI, bone scan and/or PET-CT. The primary outcome was Progression Free Survival (PFS), which was defined on the basis of no biochemical relapse (PSA<0.2ng/mL) and no need for additional treatment. Urinary continence was defined very strictly as the use of no pads. A patient was considered potent when there was the self-report of erections hard enough for penetration with or without the use of iPDE5.
RESULTS: Between September 2010 and June 2018, 82 patients were submitted to S-RARP after failed FT. Mean age at surgery was 65 [61] [62] [63] [64] [65] [66] [67] [68] [69] years Median time from FT to S-RALP was 26.5 months. Pre S-RARP mean PSA was 8.01AE3,85.
Nerve spare was performed in 75.5% of the patients (bilateral-32.7%; unilateral-36.7%; incremental bilateral-4.1% and; incremental unilateral-2%). After a mean follow up of 13 [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] months 83.1% of the patients were fully continent. 32.8% of the patients presented preoperative erectile dysfunction. Overall, 13.9% of patients were potent after surgery. There were no intra-operative complications observed. There were 5(6.1%) postoperative complications (4 Grade 1 and 1 Grade 3b METHODS: Multi-centre, international, cohort study of 164 consecutive patients submitted to S-RALP to treat PCa recurrence after primary treatment. Patients were divided in 2 groups: Group A (after EBRT/Brachytherapy, n[82), and Group B (after FT, n[82). We included patients with histological confirmation of residual/ recurrent prostate cancer within the six months previous to radical prostatectomy. In all patients metastatic disease was excluded with a pelvic MRI, bone scan and/or PET-CT. We compared both groups in terms of biochemical Recurrence Free Survival (bRFS) -which was defined on the basis of no biochemical relapse (PSA<0.2ng/mL) and no need for additional treatment; urinary continence (defined as the use of no pads), potency and perioperative outcomes.
RESULTS: From June 2007 to June 2018, 164 patients were submitted to S-RALP. Table 1 shows Baseline Characteristics and Outcomes. The positive margin rate was higher in patients submitted to S-RALP after RT(36.6% vs 13.4%, p[0.001) however the absolute biochemical recurrence rate and bRFS post S-RALP were similar in both groups. Continence rates were much higher in patients submitted to S-RALP after FT (83.1% vs. 49.3%, p<0.001). Post-operative potency rates were similar in both groups(GroupB 13.9% vs. GroupA 10.8%, p[0.6). Group A had 2 intraoperative complications (1 rectal injury and 1 ureteric injury). Post-operative complications were much higher in group A (34.1% vs 6.4%, p<0.001) (Table1).
CONCLUSIONS: Robotic prostatectomy following focal ablation therapy is associated with better functional outcome and a lower rate of postoperative complications than men undergoing surgery for recurrent disease following radiation therapy. Oncological outcomes appear similar in both Groups. Vol. 201, No. 4S, Supplement, Monday, May 6, 2019 THE JOURNAL OF UROLOGY Ò e1147
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